Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$17.50
+$0.07 (+0.4%)
Closing Price on November 7, 2024
TEVA Articles
Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity, people will...
Published:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Stocks toward the cheap consumption end of the economy tend to do better than capital goods stocks dependent on low interest rates.
Published:
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has...
Published:
ThinkstockTeva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43 in earnings per share (EPS) on...
Published:
Last Updated:
Jon OggStocks were indicated higher on Tuesday morning after 5 days in a row of selling. Yet again we see the trend of investors finding a reason to buy every stock market sell-off for bargain...
Published:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
In a deal which had been anticipated, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would buy Allergan Generics in a transaction valued at $40.5 billion. According to a press release...
Published:
Teva could be about to enter the largest generic market by prescription in the world, which may tip the scales in its favor when it comes to wooing Mylan shareholders.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Electronic Arts, Fitbit, Shake Shack, Tesla Motors, Teva Pharmaceutical Industries and Wingstop.
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published: